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Objectives: In a randomized clinical trial of patients undergoing elective coronary
artery bypass grafting, we evaluated the effect of intraoperative whole blood
sequestration and autotransfusion on postoperative blood loss and the use of allo-
geneic blood products.
Methods: Male patients were included if it was possible to obtain at least 500 mL
of autologous blood. For patients in group H (heparin autotransfusion, 50 patients;
mean age 59 8 years), an average of 670 160 mL heparinized blood was drawn
before bypass and reinfused after the period of the extracorporeal circulation. For
patients in group C (citrate autotransfusion, 48 patients; mean age 60  10 years),
450  109 mL of citrate blood, drawn before administration of heparin, was used.
Controls (N-group) consisted of 46 patients aged 62  8 years. Strict transfusion
criteria were used, and blood loss and use of allogeneic blood products during the
hospital stays of all patients were recorded. Mean differences with their 95%
confidence intervals adjusted for potential confounders were obtained by multiple
linear regression.
Results: The mean difference (95% confidence interval) of blood loss of group H
minus N was 93 mL (307 to 139) and for C minus N was 66 mL (186 to
179). The mean number of allogeneic blood transfusions for group H was 0.85 
1.74. Group C and group N used 0.94  1.56 and 0.84  1.24.
Conclusion: In coronary artery bypass grafting there is no effect of heparin or citrate
intraoperative whole blood sequestration with regard to blood loss or use of
allogeneic blood.
In recent years, the interest in blood-saving strategies has increased greatlybecause of the recognition of deleterious effects on health (acquired im-munodeficiency syndrome and immunosuppression), as well as the costaspects of blood transfusion. Coronary artery bypass grafting (CABG) hasalways claimed a considerable percentage of blood donations. Fresh bloodautotransfusion and hemodilution have been investigated for their effect in
CABG to reduce the number of blood donations. Several studies show remarkable
reductions in allogeneic blood use.1-4 However these studies are sometimes out-
dated, not randomized or controlled, or are inconclusive. Some authors suggest
inconclusive results regarding the effect of autotransfusion from the use of heparin
as an anticoagulation method.5,6 The aim of our trial was to evaluate the effective-
ness of intraoperative whole blood sequestration, comparing heparin and citrate as
anticoagulants, for decreasing blood loss and use of allogeneic blood products.
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Material and Methods
Study Design
A randomized, partly blinded clinical trial was performed in a
peripheral hospital, with all consecutive patients scheduled for
CABG during a 6-month period. After written informed consent
was obtained, patients were randomized over three groups. This
was achieved by block-randomization with concealed envelopes.
All data were registered by an independent investigator, and the
intensive care unit (ICU) staff on the ward was blinded for the
randomization. The hospital medical ethical committee approved
our study design. This was a trial where patients entered the study
when they discontinued receiving aspirin at least 7 days before
surgery. No antifibrinolytic drugs were used during the trial.
Patients
All patients scheduled for CABG were included when the follow-
ing criteria were met: male sex, age between 18 and 75 years,
normal left ventricular function test result (tested by echocardiog-
raphy), and an adequate hematocrit level and weight to allow
withdrawal of at least 500 mL of whole blood. Calculations were
based on the preoperative hematocrit level, estimated circulating
blood volume (70 mL/kg body weight is A, see formula), the
priming of the cardiopulmonary bypass (CPB) (2000 mL), and an
estimation of the volume of cardioplegic solution needed (1000
mL). We used the formula A  preoperative hematocrit level  B
 0.25 to determine the blood volume that could be safely donated
by each patient. B is the value 3000 mL, cardioplegia and pump-
priming values combined, and 0.25 is the aimed lowest hematocrit
value during bypass. Exclusion criteria were coronary artery main
stem disease, liver disease, and known or suspected bleeding
disorders.
Interventions
There were three treatment arms: a heparin autotransfusion group
(H group), a citrate autotransfusion group (C group), and a control
group (no autotransfusion, N group). In the C group, blood was
withdrawn before the initiation of the CPB and administration of
heparin. This blood was collected in routine citrate suspension to
prevent clotting. In the H group, blood withdrawal was conducted
after administration of heparin through the CPB before starting the
CPB. It is clear that the heparin was used as the anticoagulant for
the harvested fresh blood in this group. For both autotransfusion
groups, normal aseptic guidelines were followed during harvest-
ing. The blood was kept at room temperature to keep the platelet
function as optimal as possible. The targeted hematocrit level for
hemodilution for all patients was 25%. The need for fluid infusion
was closely monitored by the attending anesthesiologist; if neces-
sary extra saline solution was infused. The fresh autologous blood
was returned to the patient after protamine was given to the patient
at the end of the operation.
Transfusion Guidelines
Extensive postoperative bleeding in our department is defined as
more than 500 mL lost in the first postoperative hour, more than
400 mL lost in the second hour, or more than 300 mL lost in the
third hour. Packed cells were given if the patient had a hematocrit
level lower than 0.25 in the postoperative period combined with
extensive bleeding. Fresh frozen plasma (FFP) was given with an
international normalized ratio (INR) greater than 1.6 and extensive
bleeding. The indication for platelet transfusion was a platelet
number less than 80 combined with extensive bleeding.
Other Standard Procedures
Anesthesia was standardized to a benzodiazepine-medium opioid
and pancuronium scheme. Blood pressure was regulated with
sodium nitroprusside, and nitroglycerin 1 mg/hour was infused
routinely. Before cannulation of the aorta, heparin 300 IE/kg body
weight was given to achieve an actual clotting time (ACT) of more
than 450 seconds. The ACT was measured with a Hemo-Chron
401 (Technidyne Corp, Edison, NJ). CPB was standardized with
pump flows of 2.4 L · min1 · m2. Body surface area (BSA) at
32°C nasopharyngeal temperature and a membrane oxygenator
were used. Pump prime and cardioplegic solution were standard-
ized and contained no blood. Only moderate hypothermia down to
28°C nasopharyngeal temperature was used.
Data Collection, Statistical Analysis, and Sample Size
Calculation
Operation variables, number of bypasses, use of the internal tho-
racic artery, total clamping time, and total CPB time were re-
corded. At the ICU department, patients were monitored for blood
loss, use of allogeneic blood or blood products, hemodynamic
parameters, use of intra-aortic balloon pump (IABP), urine pro-
duction, need of ventilation, extubation time, need of rethora-
cotomy, and number of days in the ICU and the postoperative
clinical ward. Hematologic and coagulation parameters were col-
lected 1, 3, and 12 hours after surgery and at 1, 2, and 7 days after
surgery. Possible blood donations in the postoperative ward and
side effects of autotransfusion were registered. Statistical evalua-
tion took place with the SPSS statistical battery (SPSS, Inc, Chi-
cago, Ill), in which mean and standard deviations, mean difference,
and the 95% confidence intervals were calculated. We used mul-
tiple linear regression to evaluate confounding factors. To detect a
clinically significant 300-mL difference in blood loss, with an Alfa
of .05, a power 80%, and a standard deviation of 450 mL, we
calculated that we needed at least 40 patients in each group.
Results
During the period of our study, 397 men were scheduled for
CABGs, and only 144 (36.3%) patients met the inclusion
criteria. The reasons for exclusion, before the start of the
study, were a hematocrit level too low for allowing intra-
operative blood donation (n  110), a decreased left ven-
tricular function (n  51), renal or hepatic disorder (n 
34), use of heparin before the operation because of unstable
angina pectoris (n  27), lack of informed consent (n  9),
and miscellaneous (n  22). After randomization, no pa-
tients were excluded from the study or analysis of data.
Forty-six, 50, and 48 patients were randomized to the N
(normal control subjects), H, and C groups, respectively,
and all groups were comparable for the baseline character-
istics as shown in Table 1. There was a difference in the
amount of blood collection for patients in the C and H
groups. The reason for this was that it was easier to collect
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blood from the H group during CPB. For C-group patients,
collection was done before bypass through a wide-bore
intravenous catheter residing in the internal jugular vein.
Blood loss in the control group (N) and the autotransfu-
sion groups (H and C) were comparable (Table 2). The
mean blood loss in the control group was 931 mL. In the H
and C groups, the average blood loss was 1024 mL and 997
mL, respectively. The mean difference (95% confidence
interval) of blood loss of between the N and H groups was
93 mL (307 to 139 mL) and for N and C66 ml (187
to 179 mL). There were no outliers with regard to blood loss
and use of allogeneic blood products in the three groups.
Table 2 also shows that there was no reduction in postop-
erative allogeneic transfusions.
The number of packed cells transfused during the post-
operative period were 39, 43, and 45 units for the N, H, and
C groups, respectively. The percentages of patients that did
not receive homologous blood transfusions in groups H, C,
and N were 70%, 63%, and 62%, respectively. The mean
number of transfusions was 0.85  1.74 in the H group,
0.94 1.56 in the C group, and 0.84 1.24 in the N group.
The mean difference was0.02 (0.06 to 0.6) for N minus
H and 0.09 (0.7 to 0.5) for N minus C.
The units of FFP used in the autotransfusion groups were
comparable in the three groups (Table 2). Platelet donations
were more frequently used in the control group when com-
pared with citrate autotransfusion, but statistical signifi-
cance was not reached (Table 2).
Figure 1 shows the hemoglobin level for the three groups
of patients during the intraoperative and postoperative pe-
riod. The hemoglobin level for all three groups showed an
expected drop at the end of the CPB. There were no signif-
icant differences between the groups. Figure 2 shows the
mean values of the platelet number during and after opera-
tion. There are no significant differences among the H, C,
and N groups. Figure 3 shows the intraoperative and post-
operative ACT. We observed an initial increase in ACT at
the end of CPB when the heparin had not yet been antag-
onized. There were no significant differences among the
groups.
The IABP was not used in any of the patients. There was
no change in the incidence of repeat thoracotomy for bleed-
ing. The incidence of repeat thoracotomy in the control
group was 4.3% and was comparable with the 2.0% and the
6.3% of the autotransfusion groups. The mean duration of
artificial ventilation for all patients was 11  6 hours, the
mean ICU stay was 2.4  1.2 days, and the total hospital
stay was 6.2  2.5 days, with no significant differences
among the groups. No side effects were recorded in the
autotransfusion groups, and none of the patients died after
surgery.
Discussion
This study demonstrated that the use of fresh autologous
blood, administered during the operation with heparin or
citrate anticoagulation, is not effective in reducing either the
need for allogeneic blood or the postoperative blood loss.
Postoperative bleeding is believed to be partly due to the
deleterious effects of CPB on platelet function because of
activation of the clotting system.7-9 Finding no effect of
autotransfusion may be due to bias in our study protocol.
We tried to minimize information bias by using one
person to obtain the data, strict transfusion criteria, and
blinding the staff responsible for homologous blood trans-
fusions. We restricted confounding bias by use of multiple
regression to adjust for potential confounding factors. It is
possible that our inclusion criteria, donation of at least 500
mL blood, may have led to a “healthier” group or a group of
patients with a low risk of postoperative bleeding and use of
allogeneic blood use. Some randomized trials10,11 focused
retrospectively during their analysis on the question of
whether intraoperative blood sequestration was beneficial,
in a subgroup of patients undergoing CABG with a high risk
for postoperative bleeding or use of allogeneic blood, and
found a positive effect. However, we know the value of
retrospective studies.
Another reason for finding no effect could be that we
performed less optimal hemodilution. Petry and associates12
found an effect after randomization; they autotransfused
patients with their own blood after hemodilution until a
hematocrit level of 20% was reached. One quarter of our
patients had the lowest hematocrit level during bypass (be-
tween 18% and 20%). Our department aimed at a hematocrit
level of 25% to avoid hazardous and negative outcomes for
the patients. According to our data on hemostasis and the
coagulation profile during the postoperative period, we do
not expect that a lower hematocrit level would lead to a
beneficial effect because we could not observe any small
TABLE 1. Preoperative and intraoperative baseline-char-
acteristics of patients in the 3 groups: mean (SD)
N (n  46) H (n  50) C (n  48)
Age (y) 61.9 (8.1) 58.3 (8.1) 59.5 (9.6)
Weight (kg) 84 (7) 86 (8) 83 (10)
Plasma sodium (mmol/L) 139 (2) 140 (2) 139 (2)
Plasma creatinine (mmol/L) 100 (16) 97 (14) 96 (14)
ASAT (U/L) 17 (7) 18 (14) 17 (9)
Operating time (min) 256 (62) 270 (86) 250 (57)
CPB time (min) 103 (34) 105 (41) 96 (35)
Aorta clamp time (min) 70 (28) 75 (34) 67 (27)
No. of anastomoses 6 (1) 5 (1) 5 (1)
Use internal thoracic artery
(No. of patients)
41 44 45
Decreased left ventricular
function (No. of patients)
2 0 1
Volume of blood donation
(mL)
0 670 (160) 450 (109)
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positive hemostatic effects. In addition, lowering the hemat-
ocrit level during bypass to a value of, for example, 18%
will decrease oxygen-carrying capacity to a dangerous level
for the patient.
Others5,6 emphasized that the use of heparin as antico-
agulant is the reason that a possible effect of fresh blood
autotransfusion could not be measured. We tried to over-
come the problem and used citrate autotransfusion. With the
claim of reaching good hemostatic effects with citrate and
heparin autotransfusion of fresh blood,1-4 we expected that
patients receiving autotransfusion would benefit. However,
we could not confirm this. There is still a 5% chance that our
results are not true and that there is a beneficial effect of
intraoperative whole blood sequestration and autotransfu-
sion in patients undergoing CABG.
Randomized clinical trials evaluating the effect of fresh
autologous blood transfusions are scarce and inconclu-
sive.1,3,11,13 In 237 patients undergoing CABG, Wasser and
colleagues11 found differences in hemoglobin levels and
platelet count, but these were small and without clinical
significance in patients undergoing autotransfusion. Scezsi
and associates14 in 1989 and Kochamba and associates13 in
1996 reported a positive effect of fresh blood autotransfu-
sion. Reductions for allogeneic blood with 40% and 45%,
respectively, were reached. Postoperative blood loss was
reduced in these trials, with 24% and 28% compared with
control subjects. However, it should be noted that Scezsi
and associates14 did not use strict transfusion criteria or
blinding to control for information bias, whereas Kochamba
and associates13 did. Others15,16 used strict transfusion cri-
teria but included a small amount of patients during their
trial—35 and 30 patients, respectively. So we must be
careful with interpretations.
In a study by Ovrum and colleagues,4 less than 3% of
patients needed allogeneic donations during their postoper-
ative hospital stay. Important differences from our study
TABLE 2. Blood loss and use of blood products: mean differences (S.D.) between intervention groups and control subjects
H C N Mean difference 95% CI P value
Blood loss, mL 1024 576 997 475 931 483 93* 307-139 .5
66† 186-179 1
Packed red cells, units 43 45 39 0.01* 0.06-0.6 1
Units/patient 0.85 0.94 0.85 0.09† 0.7-0.5 .8
FFP, units 12 13 11 0.01* 0.29-0.29 1
Units/patient 0.24 0.27 0.24 0.03† 0.3-0.3 .8
Platelets (5 units) 4 2 5 0.03* 0.12-0.2 .7
Units/patient 0.08 0.04 0.11 0.07† 0.06-0.2 .3
FFP, Fresh frozen plasma.
*N vs H group.
†N vs. C-group.
Figure 1. Mean hemoglobin level during and after surgery.
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include their use of fresh heparinized autologous blood
combined with shed mediastinal blood; furthermore, their
study was not randomized controlled. Others17 could not
find an additional effect of autotransfusion of shed medias-
tinal blood, and clinical problems such as fever, immuno-
logic reactions, disturbances in laboratory measurements
(creatine kinase [CK] and alanine aminotransferase [ALAT]
values), wound infections,18-20 and even excessive bleeding
may occur.21 The rationale of using fresh blood without
shed mediastinal blood is that activation of platelets and
coagulation factors is prevented and improves postoperative
hemostasis.22 However, we and others11 did not observe any
positive changes regarding the hemostasis profile or platelet
count with patients receiving autotransfusion.
The value of reducing blood loss and use of allogeneic
blood was recently reappraised by Michalopoulos and col-
leagues.23 They found that the use of allogeneic blood has a
deleterious effect on survival after CABG. The mortality
rate increased if blood donations were needed in conjunc-
tion with inotropic agents in the immediate postoperative
period. The preoperative level of hemoglobin is known to be
the best predictor of the blood loss and need of allogeneic
blood.24 Other predicting factors that are influencing the use
of allogeneic blood remain to be discovered. With this trial
Figure 2. Mean platelet level during and after surgery.
Figure 3. Activated clotting time during and after surgery.
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we have one answer already. Intraoperative whole blood
sequestration, anticoagulated with heparin or citrate, does
not have a positive effect in patients undergoing CABG
when a mean volume of 670 mL or 450 mL is used in
patients at low risk. Whether there is an effect with the same
or larger volume of blood donated in patients at high risk is
yet to be examined in prospective randomized trials. A main
limitation of intraoperative whole blood sequestration and
autotransfusion seems to be the applicability towards the
patients. In our study, only 36.2% of the patients were
eligible for blood donation.
In conclusion we can say that there is no positive effect
of intraoperative whole blood sequestration and autotrans-
fusion in male patients undergoing CABG with regard to
blood loss, use of allogeneic blood, and hemostasis. The
clinical implication is that this technique is not indicated in
the patients at low risk. In the future, patient trials regarding
aggressive blood salvage techniques should focus on pa-
tients with a high risk for blood loss and use of allogeneic
blood.
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